Placulumab Biosimilar - Research Grade

Human

TNF

>1mg/ml

[V-kappa]2 - Fc

CHO Cells

Adalimumab Biosimilar - Research Grade (ICH4001), Infliximab Biosimilar - Research Grade (ICH4006), Etanercept Biosimilar - Research Grade (ICH4022), Zigakibart Biosimilar - Research Grade (ICH5291), Certolizumab Biosimilar - Research Grade (ICH5309), Golimumab Biosimilar - Research Grade (ICH5312), Afelimomab Biosimilar - Research Grade (ICH5331), Licaminlimab Biosimilar - Research Grade (ICH5643), Nerelimomab Biosimilar - Research Grade (ICH5708), Onercept Biosimilar - Research Grade (ICH5732)

https://www.imgt.org/mAb-DB/

ICH3002

P01375

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of placulumab (also known as ART621, CEP-37247 or PN0621), an anti-TNF-alpha domain antibody construct. Unlike conventional monoclonal antibodies, the originator uses a bivalent domain antibody (dAb) format built from variable-domain binders fused to a human IgG Fc region, consistent with the [V-kappa]2 - Fc architecture shown on this card. The analog is engineered around the same human TNF-alpha target (UniProt P01375) and is intended strictly for research use, not for human or veterinary use. Supplied unconjugated, it is well suited to in-vitro and preclinical research applications: as a TNF-neutralisation reference, a positive/benchmark control alongside other anti-TNF biologics, a binding and epitope tool, and a scaffold for assay development or ADCC/effector characterisation. It is manufactured to research-grade low-endotoxin specifications (<1 EU/mg; ultra-low <0.5 EU/mg options), and is available in bulk milligram-to-gram quantities to support screening, standard-curve, and formulation work. It is a research analog, not the clinical drug. Tumour necrosis factor alpha (TNF-alpha, TNF, cachectin; gene TNF, UniProt P01375; TNF superfamily member TNFSF2) is a pleiotropic pro-inflammatory cytokine produced chiefly by activated macrophages and monocytes, as well as T cells, NK cells and other cell types. It is synthesised as a 26 kDa type II transmembrane protein that is cleaved by TACE/ADAM17 to release a 17 kDa soluble form; both membrane-bound and soluble TNF assemble into homotrimers. TNF signals through two receptors, TNFR1 (p55, TNFRSF1A) and TNFR2 (p75, TNFRSF1B), driving NF-kappaB and MAPK activation, inflammatory gene expression, and apoptotic or necroptotic cell death. It is a central mediator of chronic inflammatory and autoimmune disease, making it a validated therapeutic target for TNF-blocking biologics in conditions such as rheumatoid arthritis.

Cachectin, TNF-alpha, Tumor necrosis factor ligand superfamily member 2, TNF-a, Tumor necrosis factor, TNFSF2

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks